5-((4-chlorophenoxy)methyl)-1H-pyrazol-3(2H)-one | 1227691-61-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-((4-chlorophenoxy)methyl)-1H-pyrazol-3(2H)-one
• 英文别名: 5-[(4-Chlorophenoxy)methyl]-1,2-dihydropyrazol-3-one
• CAS: 1227691-61-3
• 化学式: C₁₀H₉ClN₂O₂
• 分子量: 224.647
• InChiKey: KRUNKQITSQEHEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  ethyl 2-(4-chlorophenoxy)-acetoacetate 在 肼 作用下， 以 乙醇 为溶剂， 生成 5-((4-chlorophenoxy)methyl)-1H-pyrazol-3(2H)-one
  参考文献：
  名称：

  [EN] TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
  [FR] TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE

  摘要：

  公开号：

  WO2010059241A3

文献信息

• TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
  申请人：Kirsch Donald R.

  公开号：US20110237907A1

  公开（公告）日：2011-09-29

  The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.

  本发明涉及识别用于治疗肌萎缩侧索硬化症（ALS）和其他神经退行性疾病的化合物和药物组合物，还提供了制备所述化合物的方法。
• Treatment of Amyotrophic Lateral Sclerosis
  申请人：Silverman Richard B.

  公开号：US20160016911A1

  公开（公告）日：2016-01-21

  The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.

  本发明涉及识别化合物及其制备的药物组合物，用于治疗患有肌萎缩侧索硬化症（ALS）和其他神经退行性疾病的患者。本发明还提供了制备所述化合物的方法。
• Treatment of amyotrophic lateral sclerosis
  申请人：Kirsch Donald R.

  公开号：US10167263B2

  公开（公告）日：2019-01-01

  The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.

  本发明涉及用于治疗肌萎缩性脊髓侧索硬化症（ALS）和其他神经退行性疾病的化合物及其药物组合物的鉴定。本发明还提供了制备所提供化合物的方法。
• ADME-Guided Design and Synthesis of Aryloxanyl Pyrazolone Derivatives To Block Mutant Superoxide Dismutase 1 (SOD1) Cytotoxicity and Protein Aggregation: Potential Application for the Treatment of Amyotrophic Lateral Sclerosis
  作者：Tian Chen、Radhia Benmohamed、Jinho Kim、Karen Smith、Daniel Amante、Richard I. Morimoto、Donald R. Kirsch、Robert J. Ferrante、Richard B. Silverman

  DOI：10.1021/jm2014277

  日期：2012.1.12

  Amyotrophic lateral sclerosis (ALS) is an orphan neurodegenerative disease currently without a cure: The arylsulfanyl pyrazolone (ASP) scaffold was one of the active scaffolds identified in a cell-based high throughput screening assay targeting mutant Cu/Zn superoxide dismutase 1 (SOD 1) induced toxicity and aggregation as a marker for ALS. The initial ASP hit compounds were potent and had favorable ADME properties but had poor microsomal and plasma stability. Here, we identify the microsomal metabolite and describe synthesized analogues of these ASP compounds to address the rapid metabolism. Both in vitro potency and pharmacological properties of the ASP scaffold have been dramatically improved via chemical modification to the corresponding sulfone and ether derivatives. One of the ether analogues (13), with superior potency and in vitro pharmacokinetic properties, was tested in vivo for its pharmacokinetic profile, brain penetration, and efficacy in an ALS mouse model. The analogue showed sustained blood and brain levels in vivo and significant activity in the mouse model of ALS, thus validating the new aryloxanyl pyrazolone scaffold as an important novel therapeutic lead for the treatment of this neurodegenerative disorder.
• PYRAZOLONE DERIVATIVES USEFUL IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
  申请人：Northwestern University

  公开号：EP2367798B1

  公开（公告）日：2018-02-28